Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director, Gyo Sagara; “Ono”) announced that Ono Pharma UD Co., Ltd., which was established in April 2022 as a wholly owned subsidiary of Ono, was certified on October 18, 2022 as a special subsidiary* as stipulated in the “Act on Employment Promotion of Persons with Disabilities.”

 In the future, Ono will continue to contribute to a sustainable society by providing opportunities for employment that is rewarding for persons with disabilities, so that they can fully demonstrate their abilities and play an active role in a wide variety of jobs.

*   Special subsidiary:

Special subsidiary is a subsidiary that has been established by a company with special consideration to promote the employment of persons with disabilities based on the “Act on Employment Promotion of Persons with Disabilities”, and that has been certified as having met a certain requirement by the Minister of Health, Labour and Welfare. Under given certification, persons with disabilities who are employed in the special subsidiary can be regarded as employed in the parent company and the employment rate of these persons in the special subsidiary can be calculated together with those employed in the parent company.